产品说明书
Fexofenadine HCl
 |
同义名 : | MDL-16455 hydrochloride;Terfenadine carboxylate hydrochloride;Fexofenadine (hydrochloride);MDL 16455A;Fexofenadine hydrochloride |
| CAS号 : | 153439-40-8 | |
| 货号 : | A304995 | |
| 分子式 : | C32H40ClNO4 | |
| 纯度 : | 99%+ | |
| 分子量 : | 538.117 | |
| MDL号 : | MFCD00865710 | |
| 存储条件： |
粉末 Inert atmosphere,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(195.12 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | Fexofenadine HCl is the acid metabolite of terfenadine (Seldane). fexofenadine HCl has no significant effect on QTc(corrected QT interval), even at doses > 10-fold higher than that is efficacious for SAR(seasonal allergic rhinitis) [3]. Fexofenadine is a highly specific, H1-receptor antagonist with a safety profile similar to placebo. Fexofenadine has a high margin of safety and is also well tolerated in subjects with renal or hepatic impairment, in children and the elderly. The recommended dose of fexofenadine HC1 is 120 mg daily for SAR (either as 120 mg once daily or 60 mg twice daily) or 180 mg once daily for CIU[4]. Fexofenadine is highly selective for peripheral H(1)-receptors and does not cross the blood-brain barrier. Fexofenadine has also been shown to have a favorable effect on nasal congestion. This therapeutic advantage might be related to its significant antiallergic properties, ie, the demonstrated ability of fexofenadine to blunt the inflammatory effects of preformed and de novo synthesized mediators at clinically relevant doses in vivo and in vitro[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01375790 | Aging | Phase 3 | Completed | - | Spain ... 展开 >> Albada Centre Socio Sanitari Parc Taulí Sabadell, Babadell, Spain, 08208 Ballesol Badalona Badalona, Barcelona, Spain, 08911 Ballesol Barberà Barberà del Vallès, Barcelona, Spain, 08210 Residència Allegra Sabadell, Barcelona, Spain, 08203 Residència Poble Nou Barcelona, Spain, 08005 Ballesol Fabra i Puig Barcelona, Spain, 08016 Ballesol Almogàvers Barcelona, Spain, 08018 Residència Mapfre Quavitae Barcelona, Spain, 08025 Residència AMMA Horta Barcelona, Spain, 08035 Residència Collserola (Mutuam) Barcelona, Spain, 08035 收起 << |
| NCT02796898 | Prostate Cancer ... 展开 >> Rising Prostate Specific Antigen (PSA) 收起 << | Phase 1 Phase 2 | Recruiting | December 31, 2019 | United States, New Jersey ... 展开 >> AdvanceMed Research Completed Lawrence, New Jersey, United States, 08648 United States, New York Montefiore Medical Center- Montefiore Medical Park Not yet recruiting Bronx, New York, United States, 10461 Contact: Gartrell Benjamin, MD 718-405-8404 bgartrel@montefiore.org Eastchester Center for Cancer Care Recruiting Bronx, New York, United States, 10469 Contact: Carmen Vicuna 718-732-4078 cvicuna@nycancer.com AccuMed Research Associates Recruiting Garden City, New York, United States, 11530-1664 Contact: Tammi Allegra, RN 516-746-2190 tallegra.accumedresearch@gmail.com United States, Pennsylvania MidLantic Urology Recruiting Bala-Cynwyd, Pennsylvania, United States, 19004 Contact: Cheryl A Zinar, RN, BSN 610-667-0458 Principal Investigator: Laurence H Belkoff, DO 收起 << |
| NCT00078195 | Hay Fever Hyp... 展开 >>ersensitivity Allergy Rhinitis 收起 << | Phase 2 | Completed | - | United States, Iowa ... 展开 >> University of Iowa Iowa City, Iowa, United States, 52242 United States, Nebraska Creighton University Omaha, Nebraska, United States, 68131 United States, Wisconsin University of Wisconsin Madison, Wisconsin, United States, 53705 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.86mL 0.37mL 0.19mL |
9.29mL 1.86mL 0.93mL |
18.58mL 3.72mL 1.86mL |
| 参考文献 |
|---|